Kinetic Resolution of Racemic Hydroxy Esters via Asymmetric Catalytic Hydrogenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing optically active aliphatic alcohols are inefficient, particularly for sterically hindered compounds, and lack effective kinetic resolution methods for racemic alcohols, resulting in low enantioselectivity and limited applicability in drug synthesis.
Innovation Solution
A kinetic resolution method via asymmetric catalytic hydrogenation using a chiral spiro pyridyl phosphine ligand complexed with Iridium catalysts to achieve high enantioselectivity and yield of chiral δ-hydroxy esters and δ-1,5-diols, which can be used in the synthesis of chiral drugs and natural products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If asymmetric catalytic hydrogenation is used to prepare optically active aliphatic alcohols, then enantioselectivity can be improved, but the method is limited to sterically hindered compounds with significant differences in alkyl groups
Solution Approach 1:
The patent employs chiral catalysts with asymmetric structures (chiral phosphine ligands complexed with metal centers) to induce enantioselectivity in the hydrogenation of aliphatic carbonyl compounds. The asymmetric environment created by the chiral catalyst allows differentiation between enantiotopic faces of the carbonyl group, enabling high enantioselectivity even for substrates with similar alkyl groups that previously showed low selectivity.
2Manufacturing precision
If kinetic resolution method is used to resolve racemic alcohols, then optically active alcohols can be obtained, but the method requires significant structural differences between alkyl groups and transfers one enantiomer to ketone or ester
Solution Approach 1:
The patent converts the traditional kinetic resolution approach that discards or transforms one enantiomer into a full asymmetric synthesis approach where both enantiomers of the starting material are converted into the desired optically active product. By using chiral catalysts in asymmetric hydrogenation, the method transforms the limitation of racemic starting materials into an advantage, achieving high optical purity while maximizing material utilization as both enantiomers contribute to the final chiral product.
3Adaptability or versatility
If conventional catalytic hydrogenation is used for aliphatic ketones with similar alkyl groups, then substrate scope is improved, but enantioselectivity becomes low
Solution Approach 1:
The patent optimizes multiple parameters including catalyst composition (using specific chiral phosphine ligands and metal centers), ligand structure (modifying steric and electronic properties), solvent type, temperature, and hydrogen pressure to achieve high enantioselectivity for substrates with similar alkyl groups. These parameter changes create a more selective catalytic environment that can differentiate between enantiotopic faces even when the substrate has minimal steric differentiation.
4Manufacturing precision
If high catalyst concentration is used to achieve high enantioselectivity, then manufacturing precision is improved, but production cost and environmental impact worsen
Solution Approach 1:
The patent develops highly active chiral catalysts that operate effectively at low concentrations (0.01-1 mol%) through optimized catalyst design with enhanced turnover numbers and turnover frequencies. The self-service aspect is reflected in the catalyst's ability to maintain high enantioselectivity and catalytic activity without requiring large amounts of precious metal complexes, thereby reducing both economic cost and environmental burden while achieving the desired manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high enantioselectivity and yield of optically active chiral compounds, even at low catalyst concentrations, enabling efficient synthesis of chiral drugs like (R)-lisofylline, (+)-civet, (−)-indolizidine 167B, and (−)-coniine, with environmental and economic benefits.
Implementation Method 1
asymmetric catalytic hydrogenation using a chiral spiro pyridyl phosphine ligand complexed with Iridium catalysts
Implementation Method 2
asymmetric catalytic hydrogenation of ester group
Data Source
AI summary
The present invention relates to kinetic resolution of racemic δ-hydroxyl ester via asymmetric catalytic hydrogenation and an application thereof. In the presence of chiral spiro pyridyl phosphine ligand Iridium catalyst and base, racemic δ-hydroxyl esters were subjected to asymmetric catalytic hydrogenation to obtain extent optical purity chiral δ-hydroxyl esters and corresponding 1,5-diols. An optically active chiral δ-hydroxyl ester and 1,5-diols can be obtained at very high enantioselectivity and yield with relatively low usage of catalyst. The chiral δ-hydroxyl ester and 1,5-diols obtained by using the method can be used as a critical raw material for asymmetric synthesis of chiral drugs (R)-lisofylline and natural drugs (+)-civet, (−)-indolizidine 167B and (−)-coniine.